Home / Companies / Immuneel Therapeutics

Immuneel Therapeutics

Biotechnology / Cell TherapyBengaluru, Karnataka, India

Immuneel Therapeutics is an Indian cell and gene therapy company developing CAR-T treatments for blood cancers. Its lead product, Qartemi, is an indigenously developed CD19-targeted CAR-T therapy approved in India for relapsed or refractory B-cell lymphoma.

1StartupFox story
2019Founded
Biotechnology / Cell TherapySector
Jun 2026Latest coverage
Latest on Immuneel Therapeutics
Funding
Immuneel Therapeutics Raises Over ₹100 Crore in Series B Round to Scale Indigenous CAR-T Cancer Therapy
8 JUN 2026 · 2 MIN READ
Also in Health & Bio
VeticPet Healthcare / VeterinaryZZumutor BiologicsBiotechnology / Immuno-oncologyHoola HealthHealthcare / Paediatric ClinicsBiodimensionLife Sciences / Biofabrication
Frequently Asked
What is Immuneel Therapeutics?
Immuneel Therapeutics is an Indian cell and gene therapy company developing CAR-T treatments for blood cancers. Its lead product, Qartemi, is an indigenously developed CD19-targeted CAR-T therapy approved in India for relapsed or refractory B-cell lymphoma.
Who founded Immuneel Therapeutics?
Immuneel Therapeutics is associated with Siddhartha Mukherjee, Kiran Mazumdar-Shaw, Arun Anand.
What is the latest news on Immuneel Therapeutics?
The most recent StartupFox coverage is “Immuneel Therapeutics Raises Over ₹100 Crore in Series B Round to Scale Indigenous CAR-T Cancer Therapy” (8 June 2026). All stories are listed on this page.